文献速递心力衰竭与心肌病

急性失代偿性心衰后启动沙库巴曲缬沙坦:PIONEER-HF开放标签扩展二次分析

Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
PubMed 文献 · JAMA Cardiol · 2020-01-01

PIONEER-HF试验的开放标签扩展二次分析,纳入832例近期因急性失代偿性心衰住院的患者,比较院内启动沙库巴曲缬沙坦与院内启动依那普利后8周换用沙库巴曲缬沙坦的结局。结果显示换药后NT-proBNP进一步下降37.4%,院内启动沙库巴曲缬沙坦组12周内复合终点风险更低(HR 0.69)。

要点

  • 近期ADHF住院的HFrEF患者,院内启动沙库巴曲缬沙坦较延迟换药降低12周复合终点风险。
  • 从依那普利换用沙库巴曲缬沙坦后8至12周NT-proBNP进一步下降37.4%。
  • 已服用沙库巴曲缬沙坦者NT-proBNP自8周至12周下降17.2%。

核心结论

  • 近期因ADHF住院的HFrEF患者,院内启动沙库巴曲缬沙坦较院内启动依那普利后8周换药,12周复合终点风险更低(HR 0.69,95%CI 0.49-0.97)。
  • 从依那普利换用沙库巴曲缬沙坦后8至12周NT-proBNP进一步下降37.4%(95%CI -28.1至-45.6,P<.001)。

研究设计与样本

  • PIONEER-HF为多中心、随机、双盲、活性对照试验,2016年5月至2018年5月在美国129个中心进行。
  • 881例因ADHF住院的HFrEF且血流动力学稳定患者随机接受院内启动沙库巴曲缬沙坦或依那普利治疗8周。
  • 832例(94%)继续进入4周开放标签沙库巴曲缬沙坦研究,沙库巴曲缬沙坦滴定至97/103 mg每日两次。

主要发现

  • 继续服用沙库巴曲缬沙坦者NT-proBNP自第8周至12周下降17.2%(95%CI -3.2至-29.1)。
  • 第8周从依那普利换用沙库巴曲缬沙坦者NT-proBNP下降37.4%(95%CI -28.1至-45.6),组间变化比较P<.001。
  • 12周随访期间,院内启动沙库巴曲缬沙坦组复合终点风险低于院内启动依那普利后延迟8周换药组(HR 0.69,95%CI 0.49-0.97)。

临床怎么用

  • 对因ADHF住院且血流动力学稳定的HFrEF患者,可考虑在院内启动沙库巴曲缬沙坦而非延迟至出院后换药。
  • 已出院的HFrEF患者从依那普利换用沙库巴曲缬沙坦仍可进一步降低NT-proBNP。

局限性

  • 开放标签扩展阶段非随机比较,存在混杂可能。
  • 复合终点为探索性分析,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In PIONEER-HF, among stabilized patients with acute decompensated heart failure (ADHF), the in-hospital initiation of sacubitril/valsartan was well tolerated and led to improved outcomes compared with enalapril. However, there are limited data comparing the strategies of in-hospital vs postdischarge initiation of sacubitril/valsartan. OBJECTIVE: To describe changes in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients recently hospitalized for ADHF and switching from taking enalapril to taking sacubitril/valsartan after discharge and compare clinical outcomes for patients randomized to receive in-hospital initiation of sacubitril/valsartan vs in-hospital initiation of enalapril who later switched to taking sacubitril/valsartan during an open-label extension phase. INTERVENTIONS: Sacubitril/valsartan titrated to 97/103 mg twice daily. DESIGN, SETTING, AND PARTICIPANTS: The PIONEER-HF trial was a multicenter, randomized, double-blind, active-controlled trial conducted at 129 US sites between May 2016 and May 2018 that compared the in-hospital initiation of sacubitril/valsartan vs enalapril (titrated to target dose, 10 mg twice daily) for 8 weeks among patients admitted for ADHF with reduced ejection fraction and hemodynamic stability. All patients were to continue in a 4-week, open-label study of sacubitril/valsartan; of 881 patients enrolled in PIONEER-HF, 832 (94%) continued in the open-label study. MAIN OUTCOMES AND MEASURES: Changes in NT-proBNP levels from week 8 to 12 as well as the exploratory composite of heart failure rehospitalization or cardiovascular death from randomization through week 12. RESULTS: Of 881 participants, 226 (27.7%) were women, 487 (58.5%) were white, 297 (35.7%) were black, 15 (1.8%) were Asian, and 73 (8.8%) were of Hispanic ethnicity; the mean (SD) age was 61 (14) years. For patients who continued to take sacubitril/valsartan, NT-proBNP levels declined -17.2% (95% CI, -3.2 to -29.1) from week 8 to 12. The NT-proBNP levels declined to a greater extent for those switching from taking enalapril to sacubitril/valsartan after the week 8 visit (-37.4%; 95% CI, -28.1 to -45.6; P < .001; comparing changes in 2 groups). Over the entire 12 weeks of follow-up, patients that began taking sacubitril/valsartan in the hospital had a lower hazard for the composite outcome compared with patients that initiated enalapril in the hospital and then had a delayed initiation of sacubitril/valsartan 8 weeks later (hazard ratio, 0.69; 95% CI 0.49-0.97). CONCLUSIONS AND RELEVANCE: Switching patients' treatment from enalapril to sacubitril/valsartan at 8 weeks after randomization led to a further 37% reduction in NT-proBNP levels in patients with heart failure with reduced ejection fraction and a recent hospitalization for ADHF. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02554890.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. DeVore AD, Braunwald E, Morrow DA, et al. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. JAMA Cardiol. 2020. PMID: 31825471. doi:10.1001/jamacardio.2019.4665

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。